PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study

Autor: SIRIMA, S. B., Richert, Laura, Chene, A., KONATE, A. T., CAMPION, Cecilia, Dechavanne, S., SEMBLAT, J. P., BENHAMOUDA, N., BAHUAUD, M., Loulergue, P., NEBIE, I., Kabore, M., KARGOUGOU, D., Barry, A., OUATTARA, S. M., BOILET, Valerie, Allais, Florence, Roguet, G., HAVELANGE, N., LOPEZ-PEREZ, E., KUPPERS, A., KONATE, E., Roussillon, Caroline, KANTE, Myriam, BELARBI, L., DIARRA, A., Henry, N., SOULAMA, I., Ouedraogo, A., Esperou, H., Leroy, O., Batteux, F., TARTOUR, E., VIEBIG, N. K., THIEBAUT, Rodolphe, Launay, O., Gamain, B.

Publikováno v: The Lancet Infectious Diseases
The Lancet Infectious Diseases, New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-, 2020, 20 (5), pp.585-597. ⟨10.1016/s1473-3099(19)30739-x⟩

International audience; BackgroundPRIMVAC is a VAR2CSA-derived placental malaria vaccine candidate aiming to prevent serious clinical outcomes of Plasmodium falciparum infection during pregnancy. We assessed the safety and immunogenicity of PRIMVAC a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1bbe79b2151c7f5a4a8a3f1fb8e460c5
https://hal.archives-ouvertes.fr/hal-03161802

Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine.

Autor: Launay O; Université Paris Cité, Paris, France odile.launay@aphp.fr., Cachanado M; Hôpital St. Antoine, Paris, France., Luong Nguyen LB; Hôpital Cochin, Paris, France., Ninove L; Aix-Marseille University, Marseille, France., Lachâtre M; Hôpital Cochin, Paris, France., Ben Ghezala I; University Hospital, Dijon, France., Bardou M; University Hospital, Dijon, France., Schmidt-Mutter C; Hôpitaux Universitaires de Strasbourg, Strasbourg, France., Lacombe K; Sorbonne Université, Paris, France., Laine F; Centre Hospitalier Universitaire (CHU) Rennes, Rennes, France., Allain JS; Centre Hospitalier Universitaire (CHU) Rennes, Rennes, France., Botelho-Nevers E; CHU de Saint-Etienne, Saint-Etienne, France., Tavolacci MP; CHU Rouen, Rouen, France., Chidiac C; Hospices Civils de Lyon, Lyon, France., Pavese P; CHU de Grenoble Alpes, Grenoble, France., Dussol B; Hôpitaux Universitaires de Marseille, Marseille, France., Priet S; Aix-Marseille University, Marseille, France., Deplanque D; CHU Lille, Lille, France., Touati A; Hôpital St. Antoine, Paris, France., Curci L; Hôpital Cochin, Paris, France., Konate E; Hôpital Cochin, Paris, France., Ben Hamouda N; Hôpital Européen Georges Pompidou, Paris, France., Besbes A; Hôpital Européen Georges Pompidou, Paris, France., Nubret E; Assistance Publique-Hôpitaux de Paris, Paris, France., Capelle F; Assistance Publique-Hôpitaux de Paris, Paris, France., Berard L; Hôpital St. Antoine, Paris, France., Rousseau A; Hôpital St. Antoine, Paris, France., Tartour E; Hôpital Européen Georges Pompidou, Paris, France., Simon T; Sorbonne Université, Paris, France., de Lamballerie X; Aix-Marseille University, Marseille, France.

Publikováno v: The New England journal of medicine [N Engl J Med] 2022 Jul 28; Vol. 387 (4), pp. 374-376. Date of Electronic Publication: 2022 Jun 29.

Enzyme/pH-sensitive nanoparticles based on poly(β-L-malic acid) for drug delivery with enhanced endocytosis.

Autor: Guo, Songyan, Qiao, Youbei, Wang, Chaoli, Zhang, Yuming, Yang, Tiehong, Wu, Hong

Publikováno v: Journal of Materials Chemistry B; 12/7/2024, Vol. 12 Issue 45, p11696-11707, 12p

A Review of Protein-Based COVID-19 Vaccines: From Monovalent to Multivalent Formulations.

Autor: Qian, Gui, Gao, Cuige, Zhang, Miaomiao, Chen, Yuanxin, Xie, Liangzhi

Publikováno v: Vaccines; Jun2024, Vol. 12 Issue 6, p579, 20p

An ultra pH-responsive peptide nanocarrier for cancer gene therapy.

Autor: Wang, Zixuan, Zhang, Xuelin, Han, Mingshan, Jiao, Xinhao, Zhou, Jialin, Wang, Xinyao, Su, Rongxin, Wang, Yuefei, Qi, Wei

Publikováno v: Journal of Materials Chemistry B; 10/7/2023, Vol. 11 Issue 37, p8974-8984, 11p